Inventiva SA/ FR0013233012 /
2024-05-16 3:20:22 PM | Chg. -0.095 | Volume | Bid2024-05-16 | Ask3:20:22 PM | High | Low |
---|---|---|---|---|---|---|
3.425EUR | -2.70% | 39,082 Turnover: 135,205.030 |
3.410Bid Size: 307 | 3.425Ask Size: 97 | 3.570 | 3.400 |
GlobeNewswire
05-13
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase...
GlobeNewswire
04-03
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on For...
GlobeNewswire
03-22
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Res...
GlobeNewswire
03-18
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lan...
GlobeNewswire
03-18
PRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landma...
GlobeNewswire
03-13
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagli...
GlobeNewswire
03-07
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor ...
GlobeNewswire
02-15
Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its ...
GlobeNewswire
01-10
Inventiva draws down the second tranche of €25 million under existing Finance Contract with the Euro...
GlobeNewswire
2023-12-04
Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial wit...
GlobeNewswire
2023-11-06
Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanif...
GlobeNewswire
2023-10-09
ROTH MKM to Host Healthcare Opportunities Conference on October 12th at the Yale Club in New York Ci...
GlobeNewswire
2023-09-28
Inventiva reports its 2023 first-half financial results and provides a corporate update
GlobeNewswire
2023-09-20
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercial...
GlobeNewswire
2023-08-31
Inventiva announces a financing of approximately €35.7 million from new and existing investors, cons...
GlobeNewswire
2022-03-08
Inventiva announces that its IND application for the Phase II combination trial with lanifibranor a...
GlobeNewswire
2022-03-07
Inventiva reports its 2021 Full-Year Results: key milestones achieved with lanifibranor in NASH and ...
GlobeNewswire
2022-03-07
Inventiva publie ses résultats annuels 2021 : Avancées majeures avec lanifibranor dans la NASH et ce...